Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfò, Anastasios Stathis, Georg Stüssi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi

Blood (2022) 139 (5): 732–747.

https://doi.org/10.1182/blood.2021012386

Published: 2022

Includes: Supplemental data

Journal Articles

Whole Genome Sequencing of B-Cell Neoplasms with t(14;19)(q32;q13) Reveals Different Entities

Blood (2021) 138 (Supplement 1): 3709.

https://doi.org/10.1182/blood-2021-150891

Published: 2021

Journal Articles

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Blood (2019) 134 (Supplement_1): 4015.

https://doi.org/10.1182/blood-2019-127199

Published: 2019

Journal Articles

CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 − mantle cell lymphoma

Blood (2019) 133 (9): 940–951.

https://doi.org/10.1182/blood-2018-07-862151

Published: 2019

Includes: Supplemental data

Journal Articles

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

Francesca Guidetti, Alessio Bruscaggin, PhD, Marco Frigeni, MD, Valeria Spina, PhD, Lodovico Terzi di Bergamo, Adalgisa Condoluci, MD, Gabriela Forestieri, Francesco Bertoni, MD, Luciano Cascione, PhD, Manuela Mollejo, Véronique Meignin, Alexandra Traverse-Glehen, MD PhD, Julia T Geyer, MD, Alessandro Broccoli, Alessandra Tucci, Silvia Bea, Renzo Boldorini, Gustavo Tapia, Antonino Maiorana, Maria Gomes da Silva, MD, Juan F. Garcia, Felicitas Hitz, Michele Merli, MD, Giorgio A. Vanini, Urban Novak, Francesco Piazza, Stefano Pizzolitto, Sascha Dietrich, Liliana Devizzi, Marco Ladetto, Maurilio Ponzoni, MD, Alessandro Rambaldi, MD, Paolo Corradini, Corrado Tarella, Elisa Santambrogio, Umberto Vitolo, Francesco Zaja, Francesco Passamonti, MD, Alexandar Tzankov, Sergio Cogliatti, Carlos Montalban, Roberto Marasca, MD, Laurence de Leval, MD, Carlo Visco, Maria Joao Baptista, PhD PharmD, Vincenzo Canzonieri, Estella Matutes, Fabio Facchetti, Marco Paulli, Elias Campo, David Oscier, Elena Sabattini, Pier Luigi Zinzani, MD, Govind Bhagat, Stefano A. Pileri, MD PhD, Giorgio Inghirami, MD, Gianluca Gaidano, MD PhD, Gilles Salles, MD PhD, Catherine Thieblemont, MD, Miguel A. Piris, Franco Cavalli, MD, Emanuele Zucca, Luca Arcaini, MD, Davide Rossi, MD PhD

Blood (2018) 132 (Supplement 1): 922.

https://doi.org/10.1182/blood-2018-99-115958

Published: 2018

Journal Articles

Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms

Blood (2015) 126 (23): 3902.

https://doi.org/10.1182/blood.V126.23.3902.3902

Published: 2015

Journal Articles

Recurrent CDKN1B (p27) mutations in hairy cell leukemia

Blood (2015) 126 (8): 1005–1008.

https://doi.org/10.1182/blood-2015-04-643361

Published: 2015

Includes: Supplemental data

Journal Articles

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

Blood (2014) 124 (21): 76.

https://doi.org/10.1182/blood.V124.21.76.76

Published: 2014

Journal Articles

Clonal Selection in the Ontogeny and Evolution of Splenic Marginal Zone Lymphoma Confirming the Existence of Distinct Molecular Subtypes

Blood (2012) 120 (21): 1556.

https://doi.org/10.1182/blood.V120.21.1556.1556

Published: 2012

Journal Articles

Common variation at 6p21.31 ( BAK1 ) influences the risk of chronic lymphocytic leukemia

Blood (2012) 120 (4): 843–846.

https://doi.org/10.1182/blood-2012-03-413591

Published: 2012

Includes: Supplemental data

Journal Articles

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

Claire E. Dearden, Amit Khot, Monica Else, Mike Hamblin, Effie Grand, Ashok Roy, Saman Hewamana, Estella Matutes, Daniel Catovsky

Blood (2011) 118 (22): 5799–5802.

https://doi.org/10.1182/blood-2011-08-372854

Published: 2011

Journal Articles

Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?

Blood (2011) 118 (21): 2638.

https://doi.org/10.1182/blood.V118.21.2638.2638

Published: 2011

Journal Articles

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Ana Marin-Niebla, MD, Monica Else, MA, MSc, Fatima De la Cruz, MD, Paul Batty, MD, Eduardo Rios-Herranz, MD, Claire E. Dearden, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez Simón, MD, PhD, Daniel Catovsky, MD, Estella Matutes

Blood (2011) 118 (21): 4986.

https://doi.org/10.1182/blood.V118.21.4986.4986

Published: 2011

Journal Articles

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Carlos Montalban, MD, PhD, Victor Abraira, PhD, Luca Arcaini, Eva Domingo-Domenech, MD, Pablo Guisado-Vasco, MD, PhD, Emilio Iannitto, MD, Manuela Mollejo, MD, Estella Matutes, Andrés JM Ferreri, MD, Antonio Salar, MD, PhD, Andrea Carpaneto, MD, Ricardo Pérez, MD, Jose Luis Bello, Miguel Hernandez, Dolores Caballero, MD, Miguel A. Piris, MD, PhD

Blood (2011) 118 (21): 1583.

https://doi.org/10.1182/blood.V118.21.1583.1583

Published: 2011

Journal Articles

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Anna Skowronska, Gulshanara Ahmed, Ceri E Oldreive, PhD, David Oscier, MD, Anton Parker, Martin J.S. Dyer, MA, DPhil, Estella Matutes, MD, PhD, A. Malcolm R Taylor, PhD, Paul AH Moss, MD PhD, Tatjana Stankovic, MD PhD

Blood (2011) 118 (21): 467.

https://doi.org/10.1182/blood.V118.21.467.467

Published: 2011

Journal Articles

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification

Estella Matutes, Winfried F. Pickl, Mars van't Veer, Ricardo Morilla, John Swansbury, Herbert Strobl, Andishe Attarbaschi, Georg Hopfinger, Sue Ashley, Marie Christine Bene, Anna Porwit, Alberto Orfao, Petr Lemez, Richard Schabath, Wolf-Dieter Ludwig

Blood (2011) 117 (11): 3163–3171.

https://doi.org/10.1182/blood-2010-10-314682

Published: 2011

Journal Articles

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, Richard A Jones, Andy Rawstron, PhD, J Sheila, Paul Evans, Carter Anthony, Claire E. Dearden, MD, Estella Matutes, Andrew R. Pettitt, PhD, MRCPath, Daniel B. Kennedy, Sharon Barrans, Lisa Worrillow, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 922.

https://doi.org/10.1182/blood.V116.21.922.922

Published: 2010

Journal Articles

Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells

Blood (2010) 116 (21): 634.

https://doi.org/10.1182/blood.V116.21.634.634

Published: 2010

Journal Articles

Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL)

Andrew Hodson, MD, Silvia Montoto, MD, Naheed Mir, MD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Kate Cwynarski, MD, PhD, Kirit M Ardeshna, MD, Thurai Kumaran, MD, Estella Matutes, MD, PhD, Graham Talyor, MD, Paul Fields, MD, PhD

Blood (2010) 116 (21): 3961.

https://doi.org/10.1182/blood.V116.21.3961.3961

Published: 2010

Journal Articles

Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia

Dalemari Crowther-Swanepoel, Mobshra Qureshi, Martin J. S. Dyer, Estella Matutes, Claire Dearden, Daniel Catovsky, Richard S. Houlston

Blood (2009) 114 (23): 4843–4846.

https://doi.org/10.1182/blood-2009-07-235184

Published: 2009

Includes: Supplemental data

NARROW

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Whole Genome Sequencing of B-Cell Neoplasms with t(14;19)(q32;q13) Reveals Different Entities

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 − mantle cell lymphoma

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms

Recurrent CDKN1B (p27) mutations in hairy cell leukemia

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

Clonal Selection in the Ontogeny and Evolution of Splenic Marginal Zone Lymphoma Confirming the Existence of Distinct Molecular Subtypes

Common variation at 6p21.31 ( BAK1 ) influences the risk of chronic lymphocytic leukemia

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells

Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL)

Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only